

Amendments to the Specification:

Please replace the paragraph beginning at page 10 line 25, with the following rewritten paragraph:

With respect to dosage of CSP, whether alone or in combination with one or more additional anti-carries ~~earies~~ agents, one of ordinary skill in the art will recognize that a therapeutically effective amount will vary with the condition to be treated, its severity, the treatment regimen to be employed, the pharmacokinetics of the agent used, as well as the patient (animal or human) treated.

Please replace the paragraph beginning at page 11 line 5, with the following rewritten paragraph:

Since *S. mutans* is in direct competition with other early bacterial colonizers of the smooth surface of teeth and since many oral streptococci utilize similar glucosyltransferases to facilitate attachment, the presence of sucrose in any formulation of CSP should prove synergistic. Accordingly, the presence of sucrose in any CSP formulation or medicament of this invention will enhance the ability of glucosyltransferase dependent commensal bacteria to adhere. Thus, the combination of CSP and sucrose should both inhibit *S. mutans* attachment as well as facilitate the attachment of non-pathogenic bacteria, thus reducing the useable surface area and opportunity for *S. mutans* attachment. The plaque resulting from the attachment of non-pathogenic bacteria is benign and acts as a barrier for subsequent *S. mutans* attachment. Indeed, individuals that are edentate are devoid of *S. mutans*. Hence, CSP treatment should eventually lead to the surgical elimination of *S. mutans* from the oral cavity.

Amendments to the Claims: